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Abstract
Background Disabling respiratory symptoms and rapid
decline of lung function may occur in susceptible tobacco
smokers. Bronchial hyperresponsiveness (BHR) elicited by
direct challenge methods predicts worse lung function
outcomes. The aim of this study was to evaluate whether
BHR to isocapnic hyperventilation of dry air (IHDA) was
associated with rapid deterioration in airway status and
respiratory symptoms.
Methods One hundred twenty-eight smokers and 26 age-
and sex-matched healthy individuals with no history of
smoking were investigated. All subjects completed a
questionnaire. Spirometry and impulse oscillometry (IOS)
measurements were recorded before and after 4 min of
IHDA. The tests were repeated after 3 years in 102 smokers
and 11 controls.
Results Eighty-five smokers (66 %) responded to the
challenge with a C2.4-Hz increase in resonant frequency
(Fres), the cutoff limit defining BHR, as recorded by IOS.
They had higher Fres at baseline compared to nonrespond-
ing smokers [12.8 ± 3.2 vs. 11.5 ± 3.4 Hz (p \ 0.05)] and
lower FEV1 [83 ± 13 vs. 89 ± 13 % predicted (p \ 0.05)].
Multivariable logistic regression analysis indicated that
wheezing (odds ratio = 3.7, p \ 0.01) and coughing (odds
ratio = 8.1, p \ 0.05) were significantly associated with
hyperresponsiveness. An increase in Fres was recorded after
3 years in responding smokers but not in nonresponders or
controls. The difference remained when subjects with
COPD were excluded.
Conclusions The proportion of hyperresponsive smokers
was unexpectedly high and there was a close association
between wheezing and coughing and BHR. Only BHR
could discriminate smokers with rapid deterioration of
airway status from others.
Keywords Bronchial hyperresponsiveness  Impulse
oscillometry  Isocapnic hyperventilation of dry air 
Resonant frequency  Tobacco smoke
Introduction
Tobacco smoking may result in significant limitation of
physical performance in susceptible subjects. Hindering
symptoms such as dyspnea, coughing, and attacks of
wheezing and airway obstruction may occur, and some
smokers may experience a faster-than-normal decline of
lung function and ultimately chronic obstructive pulmon-
ary disease (COPD), a disorder characterized by systemic
and airway mucosal inflammation [1–3]. Although bron-
chial hyperresponsiveness (BHR) may occur in many dis-
eases [4], it is most common in patients with inflammatory
disorders of the airway mucosa. It has been reported in
smokers with COPD that subjects with a faster-than-normal
decline of lung function may be identified by hyperre-
sponsiveness to methacholine or histamine [5, 6]. BHR is
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also an independent predictor of mortality in patients with
COPD [7]. An extensive search for surrogate markers
capable of predicting outcomes in terms of lung function in
smokers has been conducted, and numerous studies on
serum or sputum markers of inflammation, as well as on
various tests of BHR, have been published. BHR, usually
evaluated by inhalation of methacholine or histamine, has
been found to occur in up to 85 % of smokers with COPD
[5, 8, 9]. In contrast, BHR elicited by indirect challenge
methods, such as isocapnic hyperventilation of cold or dry
air (IHDA), was reported to occur much less frequently;
only 16 % of smokers were reported to respond to IHDA
with increased airway tonus [10, 11].
Responses to bronchial challenges have been measured
mostly in terms of forced expiratory volume in 1 second
(FEV1), a technique that requires considerable patient
cooperation. A deep inhalation preceding and/or a forced
expiration during a FEV1 maneuver may alter bronchial
tone for time periods up to 6 min; this may reduce the
ability of tests to correctly identify BHR [12, 13]. Impulse
oscillometry (IOS) is an alternative technique to measure
airway status that requires minimal patient cooperation.
IOS is particularly suitable for serial measurements such as
those required during a bronchial challenge [14, 15]. Air-
way resistance, reactance, and resonant frequency (Fres) are
the outcome data; values of Fres are closely related to those
of airway resistance and are defined by the frequency at
which inertial forces are equal and opposite to elastic for-
ces (i.e., reactance is zero).
The aim of this study was to evaluate whether BHR to
IHDA, as measured by means of IOS, was associated with
deterioration in airway status relative to baseline in a
3-year follow-up study. We also examined whether the
presence of BHR was associated with subjectively per-




One hundred ninety-eight smokers attending 11 general
practitioners’ offices in Jo¨nko¨ping County, Sweden, were
invited to participate in the study. The inclusion criterion
was regular, daily tobacco smoking over at least 25 years.
Subjects with severe cardiovascular, pulmonary (other than
COPD), or systemic disease, those treated with cortico-
steroids (budesonid C800 lg or the equivalent), and those
with physician-diagnosed asthma were not included. Forty-
four subjects (30 women and 14 men) refrained from
participation due to personal reasons. Data from a further
26 smokers (23 women and 3 men) were excluded because
it was missing or the pulmonary function recordings were
nonreproducible. A complete dataset was recorded for 76
women and 52 men (Table 1). Thirty-five age- and sex-
matched subjectively healthy individuals with no history of
smoking were enrolled as controls, nine of whom were
excluded due to nonreproducible pulmonary function
recordings. A complete dataset was recorded in 17 female
and 9 male healthy controls. Baseline pulmonary function
tests were repeated after approximately 3 years in 102
smokers and 11 healthy nonsmokers. Fifteen smokers had
stopped smoking between 1 and 26 weeks prior to the first
visit and 12 had ceased smoking [12 months prior to the
second visit. Only four smokers refrained completely from
smoking during the 3-year observation period. Body mass
index (BMI) was defined as the subject’s body mass (kg)
divided by the square of his or her height (m).
All subjects completed a questionnaire regarding their
medical history, including drug therapy, smoking habits,
and respiratory symptoms. Three standardized questions
concerning symptoms associated with COPD were selected
from the International Primary Care Airways Group
Handbook [16]: (1) Does the weather affect your cough? (2)
Do you ever cough up phlegm from your chest when you do
not have a cold? (3) Do you usually cough up phlegm from
your chest in the morning? Three additional questions were
asked: Do you usually experience wheezing? Do you usu-
ally have breathing problems? Do you usually experience
shortness of breath when you have a cold?
A 3-week period free from the common cold was
required to precede the tests. Patients were asked not to use
b2-agonists, drink xanthine-containing beverages, or smoke
during the 12 hours prior to the tests. All measurements
were carried out during a single day at the Department of
Clinical Physiology, County Hospital Ryhov, Jo¨nko¨ping,
Sweden. The study complied with the Declaration of
Helsinki and was approved by the Regional Ethics
Research Committee at Linko¨ping. All subjects gave
written informed consent before inclusion in the study.
Pulmonary Function Tests
Spirometry and IOS measurements were performed using a
Masterscreen-IOS device (E. Jaeger GmbH, Wurzburg,
Germany). FEV1 and vital capacity measurements were
performed according to clinical routine and guidelines of
the American Thoracic Society and European Respiratory
Society [17, 18]. Spirometry data are given as a percentage
of reference values as documented in a national nonsmok-
ing reference population [19, 20]. The Fres was determined
by means of IOS [14, 15, 21]. The subjects wore a nose clip
and supported their cheeks with their hands. Pressure
impulses were then applied to the respiratory system via a
mouthpiece during tidal breathing. The responding signal
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was measured with a pneumotachograph and pressure
transducer. Fres was calculated from the pressure-flow
relationship by using a fast Fourier transformation. Mea-
surements were repeated at least three times at baseline and
a representative Fres value was selected. Measurements
were also repeated 2, 4, and 6 min after IHDA, and the
highest, most appropriate values were selected. Based on
duplicate measurements of responses to challenge in heal-
thy nonsmoking controls, a significant change in Fres and a
cutoff limit for BHR were defined by an increase in Fres of
C2.4 Hz (i.e., 3 9 standard deviation [SD]diff), which cor-
responds to an increase of approximately 20 %.
Hyperventilation Challenge
All subjects were encouraged to breath through a mouth-
piece at a rate of *28 breaths/min for 4 min. A gas mix-
ture containing 21 % O2, 5 % CO2, and 74 % N2 was
delivered through a calibrated rotameter to a meteorolog-
ical reservoir balloon (Ailos Asthma Test 22 000; Karlstad,
Sweden) and directed to the subject. The target ventilation
was set to 24 9 FEV1 (i.e., 70 % of maximal voluntary
ventilation) and subjects were encouraged to deflate the
balloon.
Statistical Analysis
Data are presented as mean and standard deviation, 95 %
confidence interval, or median [lower—upper quartile]. The
Mann–Whitney U test was used to test differences among
numerical variables, and Fisher’s exact test was used for
binary variables. Univariable and multivariable logistic
regression analyses were used to determine whether any
variable was associated with BHR, and the results were
expressed as odds ratios. Pearson’s correlation coefficient
was calculated to study the association between responses to
challenge and pulmonary function. Receiver-operated curve
(ROC) analyses were performed to identify smokers with
rapid deterioration in airway status. A p-value of B0.05 was
considered to be statistically significant. Two-sided tests
were used throughout. Statistical analyses were performed
using the commercially available statistical programs
STATISTICA version 9 (StatSoft Inc., Tulsa, OK, USA,
www.statsoft.com) and SAS/Stat software version 9.2 of the
SAS System for Windows (SAS Institute Inc., Cary, NC,
USA). ROC analyses were performed using MedCalc Sta-
tistical Software (Mariakerke, Belgium).
Results
Demographic characteristics, respiratory symptoms, and
the results of pulmonary function tests in 128 smokers and
26 healthy nonsmoking volunteers are given in Table 1. All
subjects were Caucasians. The smokers smoked 14 ± 8
cigarettes per day and had been smoking for 41 ± 7 years.
Thirty-eight smokers smoked less than 10 cigarettes per
day.
Eighty-five smokers showed significant increases in
Fres (i.e., C2.4 Hz) after IHDA and were classified as
‘‘responders’’ (BHR?). The remaining 43 smokers consti-
tuted a group of ‘‘nonresponders’’ (BHR-; Fig. 1). Respi-
ratory symptoms were more common in responders than in
nonresponders, and responders also had worse pulmonary
function at baseline than did nonresponders (p \ 0.05;
Table 2). Responses to challenge were not associated with
Table 1 Characteristics,
respiratory symptoms, and
pulmonary function in smokers
and healthy volunteers with no
smoking history
Values are mean ± standard
deviation or number of subjects,
unless otherwise stated
BMI body mass index b2-
agonists subjects undergoing
b2-agonist treatment, FEV1
forced expiratory volume during
1 second, VC vital capacity, Fres
resonant frequency, DFres
change in Fres after bronchial
challenge
*p \ 0.05, **p \ 0.01,







Characteristics Age (years) 58 ± 7 ns 57 ± 7
Sex (female/male) 76/52 ns 17/9
BMI 26 ± 4 *** 23 ± 2
b2-agonists 15 ns 0
Symptoms Cough affected by weather 20 ns 2
Phlegm cough without cold 71 ** 5
Phlegm cough in the morning 56 ** 3
Wheeze 86 *** 2
Breathing problems 32 ** 0
Shortness of breath on cold 54 *** 1
Pulmonary
function
FEV1 (% predicted) 85 ± 13 *** 101 ± 7
FEV1/VC (% predicted) 94 ± 11 *** 103 ± 6
Fres baseline (Hz) 12.4 ± 3.3 *** 9.6 ± 1.3
DFres (Hz) 4.1 ± 3.4 *** 1.0 ± 1.0
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baseline values of either Fres or FEV1 (r = 0.07, p [ 0.05 or
r = -0.13, p [ 0.05). Female smokers outnumbered male
smokers, and they had been regular smokers for a shorter
period of time than male smokers (40 ± 7 vs. 43 ± 6 years,
p \ 0.05); however, there were no gender-related differ-
ences in pulmonary function or IHDA response. Twenty-
nine smokers fulfilled the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria for COPD, 24 of
whom were responders [22].
Wheezing was the most commonly perceived symptom
(Table 3), and wheezers had a higher body mass index
(BMI), worse pulmonary function, and more pronounced
responses to challenge than nonwheezers. Furthermore,
coughing was associated with worse hyperresponsiveness
(p \ 0.001). In contrast, there was no association between
coughing and BMI, longer tobacco smoke exposure, or
current smoking habits.
A univariable logistic regression analysis was performed
to analyze the association between BHR and respiratory
symptoms, pulmonary function, and gender in smokers
(Table 4). These variables were also used in a multivari-
able logistic regression analysis, the results of which
indicated that wheezing (odds ratio = 3.7, p \ 0.01) and
coughing affected by weather (odds ratio = 8.1, p \ 0.05)
should remain in the logistic regression model; these fac-
tors were significantly associated with hyperresponsive-
ness. The odds ratio of BHR in smokers with a combination
of symptoms of wheezing and weather-induced cough was
21.2 times that calculated in smokers not experiencing
these symptoms.
One hundred two of the 128 smokers and 11 of the 26
healthy volunteers repeated the tests approximately 3 years
after the first visit. Baseline pulmonary function, as deter-
mined by the pretest Fres value, deteriorated significantly
more in responders [(median (lower to upper quartile,
p = 0.03) = 1.1 (-0.6 to ?4.0) Hz)] than in nonre-
sponders [0.2 (-1.0 to ?1.5) Hz] during this time period.
The corresponding change in healthy volunteers was [-0.1
(-0.7 to ?0.6) Hz]. There was no significant decline in
FEV1 (% predicted) after 3 years in responding smokers,
nonresponding smokers, or healthy volunteers [-1.1 (-6.0
to ?4.0) % and -1.0 (-6.4 to ?3.0) % vs. 1.5 (-7.6 to
?5.2) %]. Responsiveness to IHDA, but none of the other
tests or demographic data recorded at baseline during the
first visit, was capable of discriminating between those who
experienced worsening airway status and those who did
not, as defined by Fres at baseline, after the 3-year obser-
vation period. There was a small but not statistically sig-
nificant difference in deterioration of pulmonary function
after 3 years between responding and nonresponding
smokers when subjects with COPD were excluded from
evaluation [0.7 (-0.6 to ?3.9) vs. -0.1 (-0.9 to ?1.6) Hz
(p = 0.1)].
Based on the assumption that pulmonary function may
deteriorate in some of the smokers, even during such a
short period of time as 3 years, a ROC analysis was per-
formed using significant worsening of the pretest value of
Fres (i.e., increases in baseline Fres C 2.4 Hz) over time as
the classification variable. ROC analyses revealed an
alternative cutoff level of C3.8 Hz for the Fres increase.
Using the alternative cutoff level, 65 smokers instead of 85
would be defined as hyperresponsive to IHDA at the first
visit. The majority (51 %) of all responding smokers had
an Fres increase after challenge exceeding 3.8 Hz. This
higher threshold level yielded an area under the ROC curve
(AUC) of 0.66 (standard error [SE] = 0.05), sensitivity of
53 %, and specificity of 85 %. As a comparison, the cor-
responding AUC calculated using the main criterion (i.e.,
response to IHDA in individuals with Fres C 2.4 Hz) was
0.63 (SE = 0.06), and the sensitivity and specificity were
47 and 92 %, respectively. Hyperresponsive smokers, as
defined by the higher threshold level, experienced signifi-
cantly greater worsening of the baseline airway status than
those with Fres increases below this threshold (baseline Fres
changes between the two study days [2.5 (-0.3 to ?4.5)
vs. 0.1 (-1.1 to ?1.6) Hz (p = 0.005)]. The difference
between the groups remained when smokers with COPD
were excluded from evaluation [1.0 (-0.4 to ?4.1) vs. 0.1
(-1.0 to ?1.6) Hz (p = 0. 05)]. There were no differences
in the baseline FEV1 values recorded during the second





























Fig. 1 Scatterplot of change in resonant frequency (DFres) after dry
air challenge in responding smokers (BHR?), nonresponding smok-
ers (BHR-), and healthy volunteers with no smoking history
186 Lung (2013) 191:183–190
123
Discussion
Thresholds for classification of results from bronchial
challenge are arbitrary, and optimum cutoff levels must be
chosen depending on the challenge method used [23].
Measurements of IHDA responses most often have been
achieved by means of forced expirations, and a 12 %
decrease in FEV1 has been reported to be an optimal cutoff
level [23]. We used IOS for the detection of responses and
defined a positive response as an increase in Fres of at least
2.4 Hz, corresponding to a 20 % increase. Eighty-five of
128 (66 %) smokers were then recognized as responders,
and this threshold distinctly discriminated healthy indi-
viduals with no smoking history from responding smokers.
Pulmonary function at baseline, as determined by Fres,
deteriorated significantly during a 3-year observation per-
iod in BHR? smokers but not in BHR- smokers or
healthy volunteers. Although increases in baseline Fres
were modest, this still suggests that the cutoff limit of
2.4 Hz is clinically relevant, provided that a true deterio-
ration of pulmonary function occurred during this rela-
tively short period of time in BHR? smokers, despite that
FEV1 recordings were not significantly decreased in the
follow-up visit. The fact that Fres increased significantly
in BHR? smokers during the observation period but FEV1
remained unchanged tends to confirm that the IOS
technique is more sensitive than forced expirations in
measuring changes in airway function [14, 21, 24]. Fur-
thermore, as an additional sign of the higher sensitivity of
the IOS method compared to FEV1, we found only a weak
association between the levels of BHR and impaired pul-
monary function at baseline, confirming the view that IOS
recordings are independent of airflow and/or the pre-
challenge caliber of airways. A supplementary ROC anal-
ysis revealed that a Fres cutoff value of 3.8 Hz identified 65
of 128 smokers (51 %) as responders. The requirement of a
smaller decrease in Fres to define BHR? would capture
more cases of reactive airways (increased sensitivity) but
would also include some ‘‘normal’’ responses (decreased
specificity). We found no major differences in accuracy
calculated with these two different threshold levels, and
therefore the final choice of cutoff level may remain
unclear until a longer observation period has passed to
enable confirmation of the clinical significance of the
decline in airway status. Pulmonary function deteriorated
in hyperresponsive smokers, even when subjects with
COPD were excluded. Hyperresponsiveness to IHDA
Table 2 Characteristics, respiratory symptoms, and pulmonary








Characteristics Age (years) 57 ± 7 ns 58 ± 8
Sex (female/male) 50/35 ns 26/17
BMI 26 ± 4 ns 25 ± 3
Smoke years 41 ± 7 ns 41 ± 7
Cigarettes/day 14 ± 9 ns 13 ± 8
b2-agonists 15 ** 0




















83 ± 13 * 89 ± 13
FEV1/VC (%
predicted)
92 ± 11 * 98 ± 8
Fres baseline (Hz) 12.8 ± 3.2 * 11.5 ± 3.4
Values are mean ± standard deviation or number of subjects, unless
otherwise stated
BMI body mass index b2-agonists subjects undergoing b2-agonist
treatment, FEV1 forced expiratory volume during 1 second, VC vital
capacity, Fres resonant frequency
*p \ 0.05, **p \ 0.01, ***p \ 0.001, ns not statistically significant
Table 3 Characteristics and pulmonary function in smokers with and





Characteristics Age (years) 57 ± 8 ns 58 ± 7
BMI 26 ± 4 ** 24 ± 4
Smoke years 41 ± 7 ns 41 ± 7
Cigarettes/day 16 ± 8 *** 10 ± 8





83 ± 14 ** 90 ± 11
FEV1/VC (%
predicted)
93 ± 11 ns 96 ± 8
Fres baseline
(Hz)
12.9 ± 3.3 ** 11.2 ± 3.0
DFres (Hz) 4.9 ± 3.5 *** 2.5 ± 2.6
Values are mean ± standard deviation or number of subjects, unless
otherwise stated
BMI body mass index b2-agonists subjects undergoing b2-agonist
treatment, FEV1 forced expiratory volume during 1 second, VC vital
capacity, Fres resonant frequency, DFres change in Fres after bronchial
challenge
*p \ 0.05, **p \ 0.01, ***p \ 0.001, ns not statistically significant
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determined by IOS therefore appears to be a risk factor for
deterioration of pulmonary function in smokers indepen-
dent of baseline airway status or COPD.
The proportion of responders was unexpectedly high
considering that most of our smokers had only mild signs of
smoke-elicited injuries. The prevalence of BHR after
hyperventilation of cold air was previously reported to be
approximately 15 % of smokers with chronic bronchitis or
COPD. However, responses to challenge were measured by
means of FEV1, which may underestimate the true response
[25]; this could explain the low proportion of responders
among smokers upon indirect challenge in previous studies
[10, 26, 27]. Therefore, the large variability in BHR preva-
lence might depend at least partly on the methodological
limitations of the forced expiration technique, since airway
tonus may change after a deep inspiration that precedes the
FEV1 maneuver [28, 29]. Furthermore, responses to deep
inspirations have been reported to decrease with COPD
severity [30], and this may result in a larger variability in
BHR prevalence depending on differences in age distribu-
tion among the various study populations. Therefore, it is
concluded that variability in BHR prevalence among
smokers may originate from differences in challenge meth-
ods, choice of threshold levels, and/or measurement tech-
niques, apart from the phenotypical differences in
populations of smokers.
There are methodological shortcomings of the IHDA
technique per se that result from technical difficulties in
measuring and controlling airflow or alternating volumes
of exhaled warm humid air and inhaled dry cold air; this
makes the determination of ‘‘challenge doses’’ complex.
Although subjects were encouraged to reach the target
level of ventilation, some of them failed and inhaled less
than intended; this may have introduced a type II error
leading to underestimation of the number of hyperrespon-
sive subjects. Furthermore, the selection of subjects in our
study was not population-based. We recruited smokers
seeking primary health care, and selection bias theoreti-
cally might have occurred because patients with asthma or
other diseases were excluded based mainly on clinical
grounds. All our subjects were Caucasians and there might
be racial differences in vulnerability to tobacco smoke
[31]. We did not assess diet or passive tobacco smoke
exposure during childhood, factors that may influence
susceptibility. Twenty-three smokers tried to quit smoking
but only four succeeded to refrain completely from
smoking during the 3-year observation period. We could
not show that temporary or permanent cessation of smok-
ing changed the pulmonary function results between the
two study days, probably because there were too few who
refrained completely from smoking. Smoking cessation
prevents accelerated decline in lung function in all smokers
[32]. We did not exclude smokers who refrained from
smoking. We also judged that the dropout rate of 20 %
among our smokers in the 3-year observation period was
fairly large (though acceptable). Despite the fairly large
dropout rate, the number of remaining subjects allowed us
to also use data recorded during the second visit to the
laboratory.
Intermittent wheezing was the most common symptom
reported by the smokers, and there was a close association
between respiratory symptoms and BHR. Odds ratios for
the presence of BHR ranged from 3 to 20 if there was a
simultaneous history of either wheezing and/or coughing.
This may suggest parallel events and/or common under-
lying mechanisms of these particular symptoms and bron-
chial contractions elicited by IHDA. Generally, wheezers
had a worse airway status, consistent with the view that
wheezing may be a sign of airway obstruction [6]. Whee-
zers also had a higher BMI than nonwheezers, but there
was no difference in BMI between responders and nonre-
sponders. Obesity per se may be a risk factor for airways
obstruction and wheezing but not for hyperresponsiveness
[33, 34]. Our results are comparable to previously pub-
lished data in a population-based longitudinal study using
histamine challenge in the sense that hyperresponsive
subjects tended to develop respiratory symptoms more
often than those with no proven BHR [6].
We observed significant deteriorations in baseline pul-
monary function as assessed by IOS in responders, but not
in nonresponders or healthy volunteers, and this divergence
occurred after just a 3-year observation period. It is
therefore concluded that responsiveness to IHDA in
smokers may predict a decline in airway status over such a
short period of time. It is not known if BHR to IHDA is
associated with a worse prognosis in the long run, corre-
sponding to previous findings in studies on BHR to
Table 4 Odds ratios (OR) of bronchial hyperresponsiveness to
hyperventilation of dry air associated with respiratory symptoms,
pulmonary function, or gender presented with 95 % confidence
intervals (95 % CI), based on univariable logistic regression in
smokers
OR 95 % CI p
Cough affected by weather 12.3 [1.6–95.0] 0.01
Phlegm cough without cold 2.8 [1.3–5.9] 0.01
Phlegm cough in the morning 1.5 [0.7–3.2] ns
Wheeze 4.7 [2.1–10.4] 0.0001
Breathing problems 2.7 [1.0–7.2] 0.05
Shortness of breath on cold 2.1 [1.0–4.7] 0.06
FEV1 \ 80 % predicted 2.0 [0.9–4.6] 0.09
FEV1/VC \ 70 % 1.9 [0.9–4.4] 0.09
Sex, female gender 0.9 [0.4–2.0] ns
FEV1 forced expiratory volume during 1 second, VC vital capacity ns
not statistically significant
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methacholine challenge [5]. The IOS technique requires
minimal patient cooperation, is particularly suitable for
serial measurements such as those required during a bron-
chial challenge, and tends to be more sensitive than forced
expirations in measuring discrete changes in airway func-
tion. Although such changes may be detected by IOS, the
final long-term clinical relevance of the presence of BHR
detected by IHDA is not known. Future studies on the long-
term effect of smoking on BHR to IHDA and airway status
may determine whether the choice of the cutoff limit of Fres
after challenge indicates a true increased risk for the subject.
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